|
[1] RIZVI S, EATON J E, GORES G J. Primary sclerosing cholangitis as a premalignant biliary tract disease:Surveillance and management[J]. Clin Gastroenterol Hepatol, 2015, 13 (12) :2152-2165.
|
|
[2] BJOMSSON E, CHARI ST, SMYRK TC, et al. Immunoglobulin G4 associated cholangitis:Description of an emerging clinical entity based on review of the literature[J]. Hepatology, 2007, 45 (6) :1547-1554.
|
|
[3] ZEN Y, HARADA K, SASAKI M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis:Do they belong to a spectrum of sclerosing pancreatitis?[J]. Am J Surg Pathol, 2004, 28 (9) :1193-1203.
|
|
[4] NI QQ, WU HM, HUA J. An excerpt of JSGE guidelines for primary sclerosing cholangitis (2017) [J]. J Clin Hepatol, 2018, 34 (9) :1873-1876. (in Chinese) 倪茜茜, 吴惠敏, 华静.《2017年日本胃肠病学会原发性硬化性胆管炎临床指南》摘译[J].临床肝胆病杂志, 2018, 34 (9) :1873-1876.
|
|
[5] MENDES FD, JORGENSEN R, KEACH J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2006, 101 (9) :2070-2075.
|
|
[6] JIANG X, KARLSEN TH. Genetics of primary sclerosing cholangitis and pathophysiological implications[J]. Nat Rev Gastroenterol Hepatol, 2017, 14 (5) :279-295.
|
|
[7] JI SG, JURAN BD, MUCHA S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49 (2) :269-273.
|
|
[8] FOLSERAAS T, MELUM E, RAUSCH P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci[J]. J Hepatol, 2012, 57 (2) :366-375.
|
|
[9] HENRIKSEN E, VIKEN MK, WITTIG M, et al. HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry[J]. HLA, 2017, 90 (4) :228-233.
|
|
[10] BEMTSEN NL, KLINGENBERG O, JURAN BD, et al. Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis[J]. Gastroenterology, 2015, 148 (5) :924-927.
|
|
[11] HOV JR, BOBERG KM, TARALDSRUD E, et al. Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis[J]. Liver Int, 2017, 37 (3) :458-465.
|
|
[12] TANAKA A, TAZUMA S, NAKAZAWA T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan[J]. J Hepatobiliary Pancreat Sci, 2017, 24 (4) :217-225.
|
|
[13] AABAKKEN L, KARLSEN T H, ALBERT J, et al. Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline[J].Endoscopy, 2017, 49 (6) :588-608.
|
|
[14] ZHU JY, QI LG, HAN Y. Differential diagnosis and research development of primary sclerosing cholangitis and immunoglobulin G4-associated cholangitis[J]. Chin J Hepatol, 2013, 21 (2) :154-157. (in Chinese) 朱疆依, 齐林篙, 韩英.原发性硬化性胆管炎和IgG4相关性胆管炎的鉴别及诊治进展[J].中华肝脏病杂志, 2013, 21 (2) :154-157.
|
|
[15] DYSON JK, BEUERS U, JONES D, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391 (10139) :2547-2559.
|
|
[16] ZHANG LL, FAN YJ, TAN B, et al. Recognition of the clinical application and biological mechanism of ursodexycholic acid in liver diseases[J]. Chin J Clin Pharmacol Ther, 2017, 22 (2) :233-240. (in Chinese) 张林林, 樊玉娟, 谭波, 等.熊脱氧胆酸在慢性肝病中应用及机制的再认识[J].中国临床药理学与治疗学, 2017, 22 (2) :233-240.
|
|
[17] HALILBASIC E, FUCHS C, HOFER H, et al. Therapy of primary sclerosing cholangitis—today and tomorrow[J]. Dig Dis, 2015, 33 (Suppl 2) :149-163.
|
|
[18] GOLDBERG DS. Liver transplant in patients with primary sclerosing cholangitis[J]. Gastroenterol Hepatol (N Y) , 2016, 12 (2) :127-129.
|
|
[19] OSEINI AM, CHAITEERAKIJ R, SHIRE AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. Hepatology, 2011, 54 (3) :940-948.
|
|
[20] OKAZAKI K, UCHIDA K, KOYABU M, et al. IgG4 cholangiopathy:Current concept, diagnosis, and pathogenesis[J]. J Hepatol, 2014, 61 (3) :690-695.
|
|
[21] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51 (2) :237-267.
|
|
[22] BERGQUIST A, MONTGOMERY SM, BAHMANYAR S, et al.Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2008, 6 (8) :939-943.
|
DownLoad: